TY - JOUR
T1 - The effect of probiotics on gastric mucosal permeability in humans administered with aspirin
AU - Akama, Fumiaki
AU - Nishino, Ryo
AU - Makino, Seiya
AU - Kobayashi, Kiyoshi
AU - Kamikaseda, Kazufumi
AU - Nagano, Jun
AU - Koga, Yasuhiro
N1 - Funding Information:
We thank Dr. Toshiyuki Matsubara (Matsuzaki Clinic), Dr. Masamitsu Mitani (Yagi Hospital), Dr. Satoshi Terai (Hara-Doi Hospital), and Dr. Takashi Matsuoka (Furente International Co. Ltd.) for their valuable contributions in recruiting the subjects and providing technical assistance. This study was financially supported by the Research Fund of Tokai University School of Medicine. The funding source had no role in study design, data collection, or the writing of the report.
Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2011/7
Y1 - 2011/7
N2 - Objective. To examine whether a probiotic strain, Lactobacillus gasseri OLL2716 (LG21), can protect the gastric mucosal integrity from aspirin using urinary sucrose excretion (USE) test. Materials and methods. In the study using high-dose aspirin, the USE tests were carried out in 29 volunteers before and after LG21 treatment for 4 weeks. In the study using patients undergoing low-dose aspirin therapy, USE tests were performed in 37 subjects who took LG21 for 16 weeks. Stool occult blood was examined by the guaiac method. Results. In the former study, the elevation in the USE value after aspirin loading significantly decreased after LG21 treatment (Median ± SD; 0.244 ± 0.237 vs. 0.208 ± 0.112%, p = 0.018). In the latter study, the USE value significantly decreased in the period with LG21 treatment (p = 0.033), while no significant difference was found in the period without LG21 (p = 0.113). The number of positive occult blood tests decreased during LG21 treatment. Conclusions. The regular ingestion of LG21 may protect the integrity of the gastric mucosal permeability against aspirin.
AB - Objective. To examine whether a probiotic strain, Lactobacillus gasseri OLL2716 (LG21), can protect the gastric mucosal integrity from aspirin using urinary sucrose excretion (USE) test. Materials and methods. In the study using high-dose aspirin, the USE tests were carried out in 29 volunteers before and after LG21 treatment for 4 weeks. In the study using patients undergoing low-dose aspirin therapy, USE tests were performed in 37 subjects who took LG21 for 16 weeks. Stool occult blood was examined by the guaiac method. Results. In the former study, the elevation in the USE value after aspirin loading significantly decreased after LG21 treatment (Median ± SD; 0.244 ± 0.237 vs. 0.208 ± 0.112%, p = 0.018). In the latter study, the USE value significantly decreased in the period with LG21 treatment (p = 0.033), while no significant difference was found in the period without LG21 (p = 0.113). The number of positive occult blood tests decreased during LG21 treatment. Conclusions. The regular ingestion of LG21 may protect the integrity of the gastric mucosal permeability against aspirin.
UR - http://www.scopus.com/inward/record.url?scp=79960213851&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960213851&partnerID=8YFLogxK
U2 - 10.3109/00365521.2011.574730
DO - 10.3109/00365521.2011.574730
M3 - Article
C2 - 21492054
AN - SCOPUS:79960213851
VL - 46
SP - 831
EP - 836
JO - Scandinavian Journal of Gastroenterology
JF - Scandinavian Journal of Gastroenterology
SN - 0036-5521
IS - 7-8
ER -